Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.58 |
| ▸ | FABP4 | P15090 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17225885 | 0.93 | AKR1B1 (0.65) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL7584121 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL7828784 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL28442265 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL8609722 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL7083600 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL6580219 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL1527358 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL3728626 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL8865695 | 0.91 | GPR84 (0.67) | TSHRAKR1B1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797870-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING 1-[1-PHENYL-CYCLOBUTYL]ISOBUTYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9695116-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104039753-B | The compositions of phenylcycloalkyl methylamine derivative, synthesis and using method | 雷维瓦药品公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-04-28 | — | — | US | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2797870-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-104039753-A | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS INC | 2014-09-10 | — | — | CN | disclosed |
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2013102195-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-12-10 | — | — | US | disclosed |
| CN-101287842-A | Methods and compositions for determining bioactive serum paraoxonase levels | YEDA RES & DEV (IL) | 2008-10-15 | — | — | CN | disclosed |
| EP-1915457-A2 | METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020632-A2 | METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-22 | — | — | WO | disclosed |
| EP-1531672-A2 | ANTIMICROBIAL COMPOSITIONS | Novus International, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6790892-B1 | MERCAPTAN-CONTAINING HEAT STABILIZER COMPOSITION SUBSTANTIALLY FREE FROM OFFENSIVE ODOR | ROHM AND HAAS COMPANY | 2004-09-14 | — | — | US | disclosed |
| WO-2004019683-A2 | ANTIMICROBIAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | TSHR 2886/4885AKR1B1 1098/4885GPR84 545/4885 |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | TSHR 2886/4885AKR1B1 1098/4885GPR84 545/4885 |
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | PON1, LPO, PNLIP | TSHR 1678/4885AKR1B1 384/4885GPR84 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.